Frequency and Risk Factors of Primary Sclerosing Cholangitis Among Patients with Inflammatory Bowel Disease in North-East of Iran

Overview

Journal Gastroenterol Hepatol Bed Bench

Specialty Gastroenterology

Date 2015 Sep 2

PMID 26328042

Citations 7

Authors

Ahmad Khosravi Khorashad

Mohammad Khajedaluee

Elham Mokhtari Amirmajdi

Ali Bahari

Mohammad Reza Farzanehfar

Mitra Ahadi

Siavash Abedini

Mohammad Reza Abdollahi

Rosita Vakili

Hassan Vossoughi Nia

Affiliations

Soon will be listed here.

Abstract

Aim: To identify primary sclerosing cholangitis (PSC) predisposing factors in order to prevent inflammatory bowel disease (IBD) progression to PSC.

Background: IBD is commonly associated with PSC and there is no effective therapy for PSC except for liver transplantation.

Patients And Methods: This retrospective study was conducted on 447 IBD patients from IBD Clinics of Ghaem and Emam Reza Hospitals. Data were collected by interview and through a review of the patients' medical records. Patients were divided into two groups: those with IBD and PSC (IBD-PSC) and those without PSC. Variables were compared between two groups and those with statistically significant differences in IBD-PSC group were considered as predictive factors for the development of PSC.

Results: The frequency of PSC in IBDs was 4.3% and all were ulcerative colitis. The mean age of patients with PSC was 39.1±11.33 years. The male to female proportion in PSCs was 3.8:1 and in IBDs was 0.9:1. There were statistically significant associations between PSC and gender, IBD duration and UC extension, mucocutaneous involvement, oral contraceptive pills (OCP) consumption, history of surgery and history of PSC in the first- degree relatives.

Conclusion: PSC frequency among IBD patients in North-East of Iran was 4.3%. It is recommended to limit OCP consumption in IBD patients. Identification and modification of probable predisposing risk factors, as well as early diagnosis of PSC are necessary.

Citing Articles

Inflammatory Bowel Diseases Are Associated with Polymyositis and Dermatomyositis-A Retrospective Cohort Analysis.

Sharif K, Ben-Shabat N, Mahagna M, Shani U, Watad A, Cohen A Medicina (Kaunas). 2022; 58(12).

PMID: 36556929 PMC: 9781532. DOI: 10.3390/medicina58121727.

Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study.

Oh E, Kim Y, Kim M, Park S, Kim T, Park S Intest Res. 2022; 21(2):252-265.

PMID: 36453007 PMC: 10169518. DOI: 10.5217/ir.2022.00092.

Analysis of the disease activity of ulcerative colitis with and without concomitant primary sclerosing cholangitis: An investigation using a nationwide database in Japan.

Yano K, Moroi R, Shiga H, Tarasawa K, Shimoyama Y, Kuroha M JGH Open. 2022; 6(1):50-56.

PMID: 35071788 PMC: 8762614. DOI: 10.1002/jgh3.12693.

The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis-a narrative review article.

Stremmel W, Lukasova M, Weiskirchen R Ann Transl Med. 2021; 9(8):738.

PMID: 33987436 PMC: 8106090. DOI: 10.21037/atm-20-3591.

Ulcerative Colitis with and without Primary Sclerosing Cholangitis: Two Different Diseases?.

Tanaka A, Mertens J Inflamm Intest Dis. 2018; 1(1):9-14.

PMID: 29922654 PMC: 5988107. DOI: 10.1159/000445259.

References

Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G . Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2006; 11(46):7227-36. PMC: 4725142. DOI: 10.3748/wjg.v11.i46.7227. View

Saich R, Chapman R . Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008; 14(3):331-7. PMC: 2679122. DOI: 10.3748/wjg.14.331. View

Shorbagi A, Bayraktar Y . Primary sclerosing cholangitis--what is the difference between east and west?. World J Gastroenterol. 2008; 14(25):3974-81. PMC: 2725335. DOI: 10.3748/wjg.14.3974. View

Silveira M, Lindor K . Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol. 2008; 14(21):3338-49. PMC: 2716588. DOI: 10.3748/wjg.14.3338. View

Gaj P, Habior A, Mikula M, Ostrowski J . Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients. BMC Med Genet. 2008; 9:81. PMC: 2535589. DOI: 10.1186/1471-2350-9-81. View

Worthington J, Chapman R . Primary sclerosing cholangitis. Orphanet J Rare Dis. 2006; 1:41. PMC: 1636629. DOI: 10.1186/1750-1172-1-41. View

Moncrief K, Savu A, Ma M, Bain V, Wong W, Tandon P . The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience. Can J Gastroenterol. 2010; 24(1):40-6. PMC: 2830633. DOI: 10.1155/2010/830291. View

Fosby B, Karlsen T, Melum E . Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012; 18(1):1-15. PMC: 3251800. DOI: 10.3748/wjg.v18.i1.1. View

Masnadi Shirazi K, Somi M, Bafandeh Y, Saremi F, Mylanchy N, Rezaeifar P . Epidemiological and clinical characteristics of inflammatory bowel disease in patients from northwestern iran. Middle East J Dig Dis. 2014; 5(2):86-92. PMC: 3990142. View

10.

Aron J, Bowlus C . The immunobiology of primary sclerosing cholangitis. Semin Immunopathol. 2009; 31(3):383-97. PMC: 2758173. DOI: 10.1007/s00281-009-0154-7. View

11.

Florin T, Pandeya N, Radford-Smith G . Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut. 2004; 53(7):973-9. PMC: 1774125. DOI: 10.1136/gut.2003.036483. View

12.

Khoshkish S, Arefi K, Charmehali M, Vahedi H, Malekzadeh R . Risk factors for postoperative recurrence of Crohn's disease. Middle East J Dig Dis. 2014; 4(4):199-205. PMC: 3990126. View

13.

Jayaram H, Satsangi J, Chapman R . Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?. Gut. 2001; 48(3):430-4. PMC: 1760140. DOI: 10.1136/gut.48.3.430. View

14.

Itou M, Mitsuyama K, Kawaguchi T, Okabe Y, Suga H, Masuda J . Leukocytapheresis Therapy Improved Cholestasis in a Patient Suffering from Primary Sclerosing Cholangitis with Ulcerative Colitis. Case Rep Gastroenterol. 2010; 3(1):77-83. PMC: 2895181. DOI: 10.1159/000210439. View

15.

Danese S, Fiocchi C . Ulcerative colitis. N Engl J Med. 2011; 365(18):1713-25. DOI: 10.1056/NEJMra1102942. View

16.

Safarpour A, Hosseini S, Mehrabani D . Epidemiology of inflammatory bowel diseases in iran and Asia; a mini review. Iran J Med Sci. 2013; 38(2 Suppl):140-9. PMC: 3771215. View

17.

Verdonk R, Dijkstra G, Haagsma E, Shostrom V, van den Berg A, Kleibeuker J . Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006; 6(6):1422-9. DOI: 10.1111/j.1600-6143.2006.01333.x. View

18.

Shanbhogue A, Prasad S, Jagirdar J, Takahashi N, Sandrasegaran K, Fazzio R . Comprehensive update on select immune-mediated gastroenterocolitis syndromes: implications for diagnosis and management. Radiographics. 2010; 30(6):1465-87. DOI: 10.1148/rg.306105520. View

19.

Razumilava N, Gores G, Lindor K . Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011; 54(5):1842-52. PMC: 3205332. DOI: 10.1002/hep.24570. View

20.

Silveira M, Lindor K . Primary sclerosing cholangitis. Can J Gastroenterol. 2008; 22(8):689-98. PMC: 2661291. DOI: 10.1155/2008/824168. View